SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp raised its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 3.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 190,045 shares of the exchange traded fund’s stock after purchasing an additional 6,901 shares during the quarter. Stifel Financial Corp owned 0.25% of SPDR S&P Biotech ETF worth $16,969,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of XBI. Kestra Private Wealth Services LLC grew its position in shares of SPDR S&P Biotech ETF by 14.4% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 4,554 shares of the exchange traded fund’s stock worth $333,000 after acquiring an additional 574 shares in the last quarter. Western Wealth Management LLC acquired a new position in shares of SPDR S&P Biotech ETF in the 3rd quarter worth approximately $201,000. Banque Cantonale Vaudoise grew its position in shares of SPDR S&P Biotech ETF by 6.6% in the 3rd quarter. Banque Cantonale Vaudoise now owns 13,637 shares of the exchange traded fund’s stock worth $995,000 after acquiring an additional 844 shares in the last quarter. Pathstone Family Office LLC grew its position in shares of SPDR S&P Biotech ETF by 99.3% in the 3rd quarter. Pathstone Family Office LLC now owns 6,221 shares of the exchange traded fund’s stock worth $454,000 after acquiring an additional 3,099 shares in the last quarter. Finally, Aptus Capital Advisors LLC grew its position in shares of SPDR S&P Biotech ETF by 21.4% in the 3rd quarter. Aptus Capital Advisors LLC now owns 1,778 shares of the exchange traded fund’s stock worth $130,000 after acquiring an additional 313 shares in the last quarter.

SPDR S&P Biotech ETF Trading Up 2.6 %

Shares of NYSEARCA XBI opened at $91.42 on Tuesday. The company has a market cap of $6.97 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 12-month low of $63.80 and a 12-month high of $103.52. The stock’s 50 day simple moving average is $89.09 and its 200 day simple moving average is $88.74.

SPDR S&P Biotech ETF Company Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.